Illumina Ventures, a San Francisco-based early-stage venture capital firm, closed its maiden fund, at $230m.
Launched with an initial $100m investment from Illumina, Illumina Ventures has then been supported by a mix of corporate, institutional, sovereign, and individual investors.
Founded by Nicholas Naclerio, Ph.D., who was formerly SVP of corporate and venture development for Illumina, where he was responsible for corporate strategy, business development, acquisitions, spin-offs, and venture investing, Illumina Ventures is managed independently from Illumina and is focused exclusively on genomics and precision medicine, focusing on life science tools, clinical diagnostics, therapeutics, and other opportunities to improve human health.
The fund has already made investments in seven companies including Biota Technology, DNA Script, Encoded Genomics, Genome Medical, Kallyope, SerImmune, and Twist Bioscience.
FinSMEs
16/10/2017